Press Releases

Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of Fexofenadine HCl 180 mg and 60 mg tabs, plus...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging & Leisure Conference...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Executive Vice President and CFO Judy Brown will present at the 31st Annual Goldman Sachs Global Healthcare Conference on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi Investment Research Global Health Care Conference on Wednesday, May...

Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute Dextromehtorphan Polistirex Extended Release Suspension Cough...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has closed the previously announced acquisition of PBM Holdings, Inc., the world's largest manufacturer of infant formula for...

-- Fiscal third quarter revenue from continuing operations increased $32 million, or 6%, to $538 million -- Fiscal third quarter adjusted income from continuing operations increased 49% to $70...